Market
Which company partners for hypothalamus stimulation device development by end of 2025?
2
Resolution / Starting Odds
Medtronic • 25%
Boston Scientific • 25%
Abbott • 25%
Other • 25%
Press releases from EPFL, Lausanne University Hospital, or involved companies
Story
Swiss Researchers Use Hypothalamus Stimulation and Implants to Restore Walking in Paralysed Patients
Dec 2, 2024, 07:03 PM
Swiss researchers have achieved a breakthrough in spinal cord injury rehabilitation by using deep brain stimulation (DBS) targeting the lateral hypothalamus. The study, published in Nature Medicine and conducted by researchers from EPFL and Lausanne University Hospital, enabled two partially paralysed patients to regain the ability to walk short distances and climb stairs. This pioneering technique, involving electrode implants, activates residual neural connections, promoting recovery of lower limb movements. The findings were validated in preclinical models involving mice and rats, as well as in a first-in-human feasibility study. The research highlights the potential of DBS as a transformative therapy for spinal cord injuries.
View original story
Similar markets
Synchron implants more devices • 25%
Neither company implants additional devices • 25%
Both implant the same number of devices • 25%
Neuralink implants more devices • 25%
Other • 25%
Moderna • 25%
Pfizer • 25%
Johnson & Johnson • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
European Union • 25%
Switzerland • 25%
United States • 25%
Other • 25%
Google • 25%
Microsoft • 25%
Amazon • 25%
Other • 25%
Google • 25%
Amazon • 25%
Samsung • 25%
Other • 25%
WWF • 25%
Other • 25%
The Nature Conservancy • 25%
Conservation International • 25%
Yes • 50%
No • 50%
